FDA extends denecimig review: what it means for Novo Nordisk stock

Published on 10/05/2026 at 14:40 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Denecimig review extended after facility remediation. Novo Nordisk stock costs EUR 32.84 on October 5, 2026 versus EUR 33.15.

Modernes nordisches Forschungszentrum, Glasfassade, Skandinavisches Architekturdesign — Novo Nordisk A/S (DK0062498333): nordisches Forschungszentrum mit Glasfassade und klaren skandinavischen Linien, Illustration mit AI erstellt.

Novo Nordisk (ISIN DK0062498333) was trading at EUR 32.84 at Lang & Schwarz on October 5, 2026 at 2:34 p.m. CEST, down 0.94 percent versus the prior close of EUR 33.15. On October 2, 2026, the US Food and Drug Administration extended its review of denecimig because of remediation work at a manufacturing facility, according to FinanzNachrichten.

Denecimig review stays open

The FDA has not set a new regulatory decision timeline for denecimig, Novo Nordisk said in the October 2 announcement. The review concerns the treatment of hemophilia A in adults and children, while the company aims for a US launch in the first half of 2027 pending the regulatory decision.

The agency's feedback centered on facility remediation rather than clinical efficacy or safety data from the FRONTIER program. Novo Nordisk said the extended review does not change its 2026 financial outlook, giving investors a defined operational issue rather than a revised earnings forecast.

Sales growth meets weaker outlook

Novo Nordisk's second-quarter 2026 adjusted sales were DKK 78.488 billion, up 7 percent at constant exchange rates, while adjusted operating profit reached DKK 33.389 billion, up 11 percent. Both figures came from the company's August 4, 2026 results release distributed by Via Ritzau.

The contrast is material: adjusted operating profit grew 11 percent in the second quarter, yet Novo Nordisk's full-year 2026 adjusted sales and adjusted operating profit outlook remained a range of 0 percent to minus 6 percent at constant exchange rates. The guidance had improved from the earlier range of minus 4 percent to minus 12 percent.

Results date gives the next test

Novo Nordisk will announce financial results for the first three quarters of 2026 on November 4, 2026 at 7:30 a.m. CEST, according to the company's financial results calendar. That report will show whether GLP-1 volume growth can offset pricing pressure and the still-negative full-year adjusted outlook.

Quote remains below prior close

At EUR 32.84, the Lang & Schwarz quote on October 5, 2026 was EUR 0.31 below the EUR 33.15 prior close, a minus 0.94 percent daily move. The finance quote for Novo Nordisk's New York-listed ADR showed a USD 165.7 billion market capitalization and a USD 35.12 to USD 64.16 52-week range as of October 2, 2026, while the company's B shares are listed on Nasdaq Copenhagen.

The further course of trading is shown by the continuously updated real-time quote of Novo Nordisk stock.